Replies to post #405509 on Anavex Life Sciences Corp (AVXL)

[bas2020]

Seems you're making rather improbable negative assumptions, after the company has confirmed success and that detailed data is forthcoming... perhaps also a video.

I doubt we will ever a get a per protocol 30mg and 50mg set of results vs placebo.
My take is there will be no further P2b/3 data update before the peer reviewed paper.

Seems to be a lot of questionable conjecture here...

There may potentially be further specific criteria that pin points responders and of course finally how many responds better that SOC, our missing Odds Ration n. The question I have to this, if it turns out to be correct, is will the responder n be identified.

From the Odds Ratios, we already know that the treated group n was >3x and >4x than the placebo group. Using a typical placebo-effect range of 15%-20%, we can calculate/estimate that n of the treated group will be in the range of 75-100 patients exceeding threshold (perhaps more?).

Will it matter if it's 75 or 100, when the placebo group is < 1/3 the size?

I have no doubt the n's will be noted when the detailed data are released.